CTLA4 and neoplasm: In Zingg et al.’s murine B16 melanoma model, he displayed that if you combine the EZH2 inhibitor, GSK503, with IL-2 and an anti-IL-2 monoclonal antibody (NARA1) or anti-CTLA-4 therapy, there was a reduction in tumor growth [185,190].